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doi:10.1016/j.ejvs.2010.11.008Abstract Objectives: Severe neck angulation is associated with poor outcome following en-
dovascular aneurysm repair. The aim was to study the safety and early outcome of patients
with infrarenal aortic aneurysms with severe neck angulation (60e90) treated with the
Aorfix endovascular stent graft.
Design/methods: This was a non-randomized prospective observational study of 30 patients
with infra-renal abdominal aortic aneurysms with highly angulated necks. Outcomes were
primary technical success, 30 day and short term (30 dayse6 months) clinical success and other
patient morbidity at 30 days.
Results: Median neck angulation was 81.2. Initial technical success was 93.3% (nZ 28) with 2
stents deployed too low. Intra-operatively 3 patients initially had type I endoleaks, but all
were resolved by ballooning. 30 day clinical success was 96.7%: there were no type I or type
III endoleaks observed, and no reports of graft thrombosis or migration. Early clinical failure
was accounted for by one perioperative death (3% mortality). No aneurysm-related interven-
tions were required during follow-up. At 6 months two patients were reported as having type
I endoleaks, although both sacs have reduced in size. Neither has required intervention. No
patient has died due to aneurysm rupture or required removal of the endograft.
Conclusion: The results of this study support the continued application of the Aorfix graft to
the highly angulated neck.
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Endovascular repair (EVAR) is now increasingly applied1
and accepted as a treatment for infra-renal abdominal
aortic aneurysms.2,3 The suitability of a patient for EVAR
is dependent on the patient’s aorto-iliac anatomy
adhering to the manufacturer’s instructions for use (IFU).
Typically manufacturers recommend a neck length of
minimum 15 mm (10 mm for Endurant Stent Graft System
(Medtronic, Inc, Santa Rosa, California)), <60 infrarenal
neck angulation (<75 infrarenal angulation where neck
length is >15 mm for the Endurant), and a proximal neck
diameter of up to 32 mm with 10e20% oversizing of the
graft. Non-adherence to the IFU is strongly associated
with poorer outcomes, particularly type I endoleaks.4,5
Despite this, over a ten-year period, over 20%
(n Z 1152) of patients recorded in the EUROSTAR EVAR
registry had aneurysms with severe neck angulation
(>60). There were significant increases in proximal
endoleaks, graft migration and neck dilatation in this
subgroup.6
The Aorfix aortic stent graft is a modular device
composed of a circular Nitinol frame covered by a woven
polyester fabric. This structure, in contrast to the rigid z-
stent design of other commercially available stent grafts, is
extremely flexible and readily compliant with tortuous
vessels (Fig. 1). A previous prospective multicentre study
has demonstrated the utility of the Aorfix stent in
patients with infrarenal neck angulation of up to 65.7
Furthermore bench testing has shown that unlike other
grafts, neck angulation has no influence on type I endoleak
rate with the Aorfix device.8
The aim of this prospective multicentre trial was
therefore to study the safety and early outcome of
patients with infrarenal aortic aneurysms with severe
neck angulation (60e90) treated with the Aorfix stent
graft.Figure 1 Aorfix stent graft in a patient with highly angulated a
aortic aneurysm with neck angulation of just under 90; intra-opera
operative CT (c) and (d) demonstrate the conformity of the graftMethods
Study design
This was a prospective non-randomized observational study
conducted across 9 European centres. Recruitment and
treatment of patients occurred between June 2006 and
September 2008. The device and technique has been
described in detail previously.7
Patients were considered eligible for the trial if they
had an abdominal aortic aneurysmof>50mmdiameter,with
an infrarenal neck length>15mmand angulation of between
60 and 90 as assessed by CT scan in 3 dimensions. Patients
also required aorto-iliac anatomy for endovascular aneurysm
repair in keeping with the previously published IFU for the
Aorfix device7 (i.e. a non-aneurysmal neck length of
>15 mm below the renal arteries and >20 mm below the
superior mesenteric artery; common iliac artery diameter
must be greater than 7mm(innerwall to innerwall)), with an
appropriate distal landing length (minimum 9 mm). Patients
with connective tissue diseases and renal failure (creatinine
>176 mmol) were not eligible for the study. Patients outside
the anatomical criteria (e.g., angulation >90) could be
treatedwith the graft as part of the studywith local consent.
The study protocol required all patients to be assessed
at 72 h or discharge, 30 days and 6 months post procedure.
Assessment at 30 days was either with duplex ultrasound
or CT dependent on the preference of the clinician.
All patients underwent CT angiography at 6 months.
Outcomes
The outcomes assessed were technical success, early clin-
ical success, early morbidity, short term clinical success
and stent migration rate. We have reported outcomes on
the basis of intention to treat.natomy; pre-operative CT (a) shows an infra-renal abdominal
tive DSA (b) demonstrates the positioning of the graft and post-
to the patient’s anatomy.
Table 2 Anatomical features.
Aneurysm morphology Mean (range)
Mean Size 69.3 mm (55e109 mm)
Infra-renal angulation 81.2 (63e110)
Neck length 26.2 mm (11e40 mm)
Neck diameter 24.4 mm (19.2e29.2 mm)
Other features n
Adverse neck shape
Conical 4
Barrel 6
Neck calcification
Moderate 14
Severe 5
Excessive neck thrombus 0
Iliac tortuosity
Moderate 11
Severe 10
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procedural events occurring from the start of the procedure
and extending through the first 24 h) involves the following
components: successful access to the arterial system using
a remote site; successful deployment of the endograft
with secure proximal and distal fixation with the absence of
type I or III endoleak and a patent graft without significant
twist, kink or obstruction. Technical success includes the
use of adjuncts including modular components, stents,
angioplasty or surgical procedures. If these adjuncts are
unplanned then the term assisted primary technical
success is applied. Clinical success is defined as “successful
deployment of the endovascular device at the intended
location without death as a result of aneurysm-related
treatment, type I or III endoleak, graft infection or
thrombosis, aneurysm expansion (diameter <5 mm, or
volume <5%), aneurysm rupture, or conversion to open
repair”. Clinical success was measured at 30 days (early)
and between 30 days and 6 months (short term).
Beyond the planned duration of the study, data has been
collected on an annual basis and 12 month follow-up
outcomes are also reported in this study.Results
Patient demographics and aneurysm morphology
30 patients were recruited and underwent treatment.
Demographics and aneurysm morphology are summarized
in Tables 1 and 2.
Procedural information
Epidural anesthesia was used in the majority of cases
(n Z 23). The mean duration of operation was 134 min
(range: 35e271 min), with a mean screening time of 34 min
(range 10e81 min). Mean blood loss was 335 ml (range:
80e1700 ml), with four subjects requiring a blood trans-
fusion. Fifteen patients were managed post-operativelyTable 1 Patient demographics.
Demographics
Male sex 23
Mean age 77.4 yrs (Range 59e95)
Co-morbidity n
Smoking
Current 6
Ex 18
Previous MI 10
Hypertension 11
Chronic obstructive
pulmonary disease
5
Renal impairment 8
Anti-platelet use 19
ASA grade
ASA II 13
ASA III 16
ASA IV 1on intensive care for at least 1 day (range 1e3). Mean
inpatient length of stay was 4.5 days.
Protocol violations
7 patients were treated outside the eligibility criteria of the
trial, 2 with elevated serum creatinine >176 mmol, 4 with
a neck angle of greater than 90 (92, 96, 99, 110) and 1
with neck length less than 15 mm (11 mm). The principal
investigator in each centre made the clinical decision to
enter the patient into the study.
Follow-up
Per-protocol 30 day follow-up data was available for 29
patients and six month data was available for 27 of the 30
patients (patient deaths n Z 3). 12 month CT has been
performed in 21. Three further patients are alive, but have
not been imaged and the three remaining patients are lost
to follow-up.
Outcomes
Technical success
There were two primary technical failures, where the
device was positioned too low to gain secure proximal
fixation and an unplanned proximal extender was used.
Three patients had a type I endoleak following deployment;
however all were obliterated on completion angiography
by ballooning. As ballooning is a planned adjunct for the
deployment of the Aorfix stent graft these cases should
not be considered to be primary technical failures.9 Primary
technical success was 28/30 (93.3%) and assisted primary
technical success was 30/30 (100%). No patient required
conversion to an open aneurysm repair.
Three patients had the endograft inaccurately deployed
resulting in partial or complete coverage of a visceral aortic
branch. In one patient a renal artery was partially covered
340 A.R. Weale et al.without change in measured renal function. Two patients
had inaccurate placement of an iliac limb resulting in
inadvertent coverage of an internal iliac artery. One of
these patients suffered mild buttock claudication. Despite
deployment too high or too low (adverse events) these
patients satisfy the definition of technical success as the
aneurysm was excluded with a patent graft, and without
type I or III endoleak.9
30 day clinical success
There was one death within 30 days. This patient developed
a critically ischaemic leg post procedure due to a right
superficial femoral artery occlusion requiring angioplasty
and stenting. Following this (day 2 post-operatively) he
developed abdominal pain, hypotension and a lactic
acidosis; at laparotomy he was found to have infarcted
intestine due to occlusion of the superior mesenteric artery
(SMA). The patient did not undergo post mortem examina-
tion and it is unknown whether the stent graft was
occluding the origin of the artery.
There were no type I or type III endoleaks at 30 days.
6 patients had aneurysm sacs which were measured as
larger than on the pre-procedural scan; with a mean
expansion of 2 mm (range 1e4 mm), although no patient
had aneurysm expansion of >5 mm or 5% volume. There
were no reports of graft thrombosis, infection, migration,
aneurysm rupture or conversion to open repair. 30 day
clinical success was 29/30 (1 death) e 96.7%.
30 day morbidity
Five patients had local-vascular complications (16.6%). One
patient had significant haemorrhage from the femoral
artery during the procedure. Two patients had limb
threatening ischaemia in the early post operative period;
one of whom has already been described. The second
patient had thrombotic occlusion of the common femoral
artery and required thrombectomy and common femoral
endarterctomy 2 days post procedure. One patient had
distal embolisation to the fifth toe. This required amputa-
tion of the affected digit. Finally one patient with
a covered internal iliac artery had mild buttock claudica-
tion as described.
There were four subjects who had minor post operative
wound problems (seromas n Z 3 and wound infection
n Z 1; 13.3%).
Two patients’ serum creatinine levels became abnormally
raised post procedure (138 mmol/l and 147 mmol/l). No
patient required renal support within 30 days. Both patients’
creatinine remained elevated at 6 months (138 mmol/l and
157 respectively mmol/l). The cause of renal impairment is
unknown. One patient developed a bradycardia on day
one post operation; this required temporary placement of
a pacing wire for 48 h. One patient developed a post-oper-
ative chest infection (day 7).
Short term clinical success (30 dayse6 months)
There were two further deaths, although neither aneurysm-
related. The first patient required a permanent pacemaker1 month post procedure, and despite a normal creatinine
at the time of procedure was dialysis dependent 3 months
post operation (aetiology unknown). The subject developed
angina and left ventricular failure and suffered a fatal
cardiac arrest 121 days post procedure. The second patient
developed acute renal failure due to Clostridium difficile
infection, and died 168 days post procedure due to a chest
infection.
Two type I endoleaks were observed at 6monthse both of
these are recurrent. Neither patient has sac expansion;e as
such the local investigators have adopted a conservative
approach in both patients. There were no reported type III
endoleaks, graft thrombosis, infection, migration, aneurysm
rupture or conversion to open repair. Clinical success
between 30 days and 6 months was therefore 25/27 e 92.6%
(failure in 2 patients with type I endoleak).
Six patients had expansion of the aneurysm sac from
baseline scanning, with a mean increase of 3 mm. Four
patients had no change in sac size, whilst 15 had a reduc-
tion in sac diameter (mean 6.7 mm).
12 month clinical success
All 24 of the patients with follow-up data to one year are
alive, with no aneurysm rupture, graft thrombosis or
infection. Of the 21 patients who have undergone imaging
there were no reports of graft migration. There have been
no interventions in this time period. Mean aneurysm sac
size has decreased by 6.1e63.2 mm (14 patients- decrease
in sac size; 6 patients no change and 1 patient- increase
2 mm).
One patient has a persistent type I endoleak at 12
months but has had no change in sac diameter. The second
subject who was reported as having a type I endoleak at 6
months, was reported at 12 months as having a type II
rather than a type I endoleak. The aneurysm sac in this
patient had decreased from 66 mm to 64 mm.
Discussion
This study has demonstrated that the Aorfix device can be
used to treat patients with aneurysms with highly angulated
infra-renal necks with high short term technical and clinical
success.
In this study of 30 patients all had neck angle of >60
and nineteen (63%) had a neck angle of >75. The level
of primary technical success in this study (93.3%) is compa-
rable with the performance of other contemporary
commercial devices applied to far less angulated neck
anatomy e for example the Medtronic Endurant graft
system had a success rate of 90.3%10 in a study of patients
with neck angulation of up to 75. However, only six
patients (15%) in this study had neck angulations of >60.
In a further study of the Endurant11 graft the authors report
a “30 day technical success rate of 44/45 (97.8%) and clinical
success rate of 43/45 (95.6%)”. In this study 26(58%) patients
in the cohort had a neck angle of>60. However the authors
have used different definitions of success to that which is
recommended.9 Five patients required unplanned intra-
operative adjuncts (iliac stenting); as such primary technical
success was only 88.8%.
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(n Z 512) the level of technical and/or clinical success is
not defined. However the use of unplanned adjuncts
(extenders n Z 114, cuffs n Z 16, non-covered stents
nZ 18) was extremely high (nZ 148; 28.6%); thus primary
technical success was just over 70%.2 Furthermore in the
first 30 days 8 patients died, 10 required conversion to open
repair, and 18 patients required a secondary intervention
for endoleak. Thus the level of clinical failure was at least
37/512 (7.0%).12 We report early clinical success rate of
96.7% in a group of patients with what had previously
considered highly unfavorable anatomy. Indeed over a third
of patients had severe iliac angulation as well as severe
neck angulation, which is recognized as an issue in EVAR.13
The technical failures in our study occurred due to low
deployment e both successfully managed by a proximal
extension. This problem was also noted by Albertini7 in
a similar sized series of patients with less severe angulation,
where four patients (14.0%) had the graft deployed too
low. There was also inaccurate deployment in three other
patients e these are adverse events and not technical or
clinical failures. Two patients, both of whom had neck
angulations of >90, had unplanned coverage of internal
iliacs. The third had partial coverage of a renal artery
without clinical consequence. The top end of the Aorfix
graft has a “fishmouth” and requires accurate orientation of
the graft. Ideally the graft should be deployed with the
troughs embracing the renal ostia and the anterior peak of
the fish mouth positioned below the origin of the superior
mesenteric origin. Highly angulated anatomy creates fore-
shortening and often requires angulation of source and
detector during deployment and angiography,14 whilst iliac
angulation may make it difficult to rotate the stent graft,
as required for orientation of the fish mouths. It is undis-
putable that there is a learning curve for treating such
complex anatomy, in addition to using the Aorfix graft. The
clinical and technical failures in this study should be
considered in this context.
One patient died in this study, giving a 30 day mortality of
3.3%. Although this mortality rate is higher than large
prospective randomized studies comparing open and endo-
vascular aneurysm repair,2,3,15 the average age of the
patients in this study was over five years older. Themortality
rate is in keeping with contemporary single centre series
which range from 016e8%17 .In particular the mortality rate
is lower than the 4.0% mortality reported for patients
with severe neck angulation in the Eurostar registry.6 It is
undisputed that the death in the study patient was related to
the treatment of the aneurysm, however it is not possible
to ascertain the exact role the stent played as the patient
did not undergo a post mortem examination.
At six month the aneurysm-related and all cause
mortality rate in this series was 3.3% and 10% respectively.
It is likely the deaths outside the perioperative period
reflect the co-morbidity of this elderly cohort, although
only two patients in this series had been formally turned
down for open repair.
The level of morbidity following EVAR is often un-
reported e for example 30 day morbidity is not reported in
EVAR 1.12 Four patients in this study had wound related
problems (seroma, haematoma or infection). We acknowl-
edge that these minor complications are reported ata higher rate than in other trials (e.g., DREAM 3.5%). In the
DREAM3 trial 16.4% of patients had a local-vascular or
implant related complication. This is similar to the rate
described in our study: two patients had limb threatening
ischaemia (including the subject who died), one had distal
embolisation, one had significant groin haemorrhage per-
procedure and one had claudication due to coverage of
the internal iliac (5/30 e 16.6%). Overall, at thirty days the
level of secondary intervention was 10% (two operations for
limb ischaemia likely related to underlying femoral disease
and one minor amputation). It is worthy of note that
vascular complications are probably far more frequent
than previously thought e a recent study of 134 patients
found that 25% had a significant common femoral or
external iliac dissection on duplex following endograft
placement.18 The authors state that dissection was unre-
lated to device type; as such the local complications in this
study should not simply be attributed to the device used in
this series.
The Eurostar data6 has shown that use of the Talent
(Medtronic), Zenith (Cook) and Excluder (Gore) stent
grafts in patients with severe neck angulation is associated
with greater than two fold increase in both early (30 day)
type I endoleak and stent migration. At 30 days, 4.9% of
the 1152 patients with severe neck angulation had a type I
endoleak and 1.6% of stent grafts had migrated. A recent
single centre, device specific performance study in high
angled neck aneurysms, found that the Zenith (Cook) and
the Talent (Medtronic) grafts had a 19% and 53% proximal
type I endoleak rate respectively (median 16 month follow-
up).19 It is suggested that suprarenal fixation may reduce
adverse events associated with hostile neck anatomy;
however graft kinking and infolding may be a problem with
angulation of >60.20 The concentric nitinol ring structure
of the Aorfix stent graft provides conformability in severe
angulation without kinking. Despite a lack of supra-renal
fixation, prospective studies in patients with high neck
angulation have shown no evidence of Aorfix graft
migration.7
In this study at 30 days, no patient had a type I endoleak
detected and there was no evidence of any graft migration.
These results are promising; they clearly improve upon
the Eurostar data, which is only directly comparable at 30
days (4.9%). However at 6 months, 2 patients were reported
as having developed a proximal type I endoleak. Neither
have any evidence of graft migration or sac expansion;
indeed the sacs have reduced in size by 1 mm and 3 mm
respectively. It is worth re-iterating that the diagnosis of
all endoleaks and treatment decisions were made by indi-
vidual practitioners. Both patients with type I endoleaks at
6 months had required intra-operative ballooning prior to
completion angiography to abolish apparent type I endo-
leaks. The first subject, an 83-year-old female had a neck
angle of 90, with a 20 mm neck which was barrel shaped
and 22 mm in diameter above an aneurysm of 67 mm. The
presence of a non-parallel neck increases the risk of prox-
imal endoleak.21 However at 12 months, this patient was
reported as having a type II and not a type I endoleak.
Furthermore the sac size has decreased further, suggesting
this is a benign endoleak. The second subject, a 77-year-old
male had a neck diameter of 29 mm, neck length of only
11 mm, neck angle of 71 and an aneurysm of 61 mm. The
342 A.R. Weale et al.short aneurysm neck is outside the eligibility criteria of
the study but a decision to proceed was made locally.
Short neck length is a risk factor for late type I endo-
leaks5,21 and in this patient the endoleak persisted at 12
months with no change in sac size. The Eurostar data
suggests that the relative risk of late proximal endoleak in
patients with neck 10e14 mm (9.6%) is twice that of
patients with a length of >15 mm (3.4%). However this was
not associated with increased risk of re-intervention, sac
expansion or aneurysm-related death. Both patients will
be followed closely and longer term results regarding
re-intervention in this study group are keenly anticipated.
Importantly in this study, once beyond the first 30 days, no
subject has undergone any form of re-intervention.
We fully acknowledge that this is a small study, which has
limitations. It is a highly selected population with a high-
number of local violations to inclusion criteria, particularly
relating to neck angulation. The inclusion of such patients in
the trialwas amatter of local consent; however it is important
to emphasise that these patients did not have anatomywhich
conformed to the IFUs of other currently available. In terms of
selection bias; the study did not collect information on
patients with suitable anatomy who were excluded from the
trial. Despite this potential bias, the study remains a trans-
parent assessment of the graft in patients with highly angu-
lated anatomy. The number of patients in the study is smalle
with only 25 adhering to the anatomical inclusion parameters.
Whilst some may argue that apparent high clinical success in
such a sized group is a type II error e it is also true that any
morbidity and mortality is potentially magnified. However,
such numbers are usual for this type of early safety and effi-
cacy study. For example the initial Talent graft study reported
30 day outcomes for just 25 patients.22 It is worthwhile noting
that in this study group the initial technical success was just
78% and the 30 day mortality was 12% (3 patients).
We contend that despite the methodological limitations
of this study, the results support the continued application
of the Aorfix stent graft to the highly angulated neck.
Data from this study and the Retrospective Aorfix Data
Retrieval (RADAR) registry has confirmed graft safety and
good clinical outcomes allowing a CE marking and IFU
allowing the treatment aneurysms with up to 90 neck
angulation. Long term follow-up and larger studies are
required to evaluate the durability of the early results.
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